Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(S)-alpha-tetralol + NADP+
alpha-tetralone + NADPH + H+
-
-
-
?
(S)-tetralol + NADP+
? + NADPH
-
-
-
?
1,2,3,4-tetrahydro-1-naphthol + NADP+
1,2,3,4-tetrahydro-1-naphthone + NADPH
-
isoenzymes 1 and 2
-
r
1-acenaphthenol + NADP+
1-acenaphthenone + NADPH
-
isoenzymes 1 and 2
-
r
11-hydroxy-androstenedione + NADPH
11beta-hydroxy-testosterone
11-ketoandrostenedione + NADPH
11-ketotestosterone + NADP+
17beta-estradiol + NADP+
estrone + NADPH
19-nortestosterone + NADP+
19-norandrostenedione + NADPH
-
93% activity compared to testosterone oxidation
-
r
4-oxo-2-nonenal + NADPH + H+
4-hydroxy-2-nonenal + NADP+
-
-
-
?
5alpha-androstane-17beta-ol-3-one + NADP+
5alpha-androstane-3,17-dione + NADPH
-
30% activity compared to testosterone oxidation
-
r
5alpha-androstane-3alpha,17beta-diol + NADP+
5alpha-androstane-3alpha-ol-17-one + NADPH
5alpha-androstane-3beta,17beta-diol + NADP+
5alpha-androstane-3beta-ol-17-one + NADPH
5alpha-dihydrotestosterone + NADP+
5alpha-17-oxo-dihydrotestosterone + NADPH
-
isoenzymes 1 and 2
-
r
5beta-androstane-17beta-ol + NADP+
5alpha-androstane-17-one + NADPH
-
117% activity compared to testosterone oxidation
-
r
5beta-androstane-17beta-ol-3-one + NADP+
5beta-androstane-3,17-dione + NADPH
-
330% activity compared to testosterone oxidation
-
r
5beta-androstane-3alpha,17beta-diol + NADP+
5beta-androstane-3alpha-ol-17-one + NADPH + H+
5beta-androstane-3beta,17beta-diol + NADP+
5alpha-androstane-3beta-ol-17-one + NADPH
-
-
-
-
r
5beta-dihydrotestosterone + NADP+
5beta-17-oxo-dihydrotestosterone + NADPH
9,10-phenanthrenequinone + NADPH
?
-
-
-
-
?
androst-4-ene-3,17-dione + NADPH
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
testosterone + NADP+
-
-
-
-
?
androstanedione + NADPH
dihydrotestosterone + NADP+
-
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
androsterone + NADPH + H+
androstane-3beta,17beta-diol + NADP+
-
-
-
-
?
benzene dihydrodiol + NADP+
o-benzoquinone + NADPH
-
isoenzymes 1 and 2
-
r
cyclohex-2-en-1-ol + NADP+
cyclohex-2-en-1-one + NADPH
-
isoenzymes 1 and 2
-
r
dehydroepiandrosterone + NADPH
androst-5-en-3beta,17beta-diol + NADP+
dehydroepiandrosterone + NADPH
androst-5-ene-3beta,17beta-diol + NADP+
-
-
-
r
epiandrosterone + NADPH
androstane-3beta,17beta-diol + NADP+
indan-1-ol + NADP+
indan-1-one + NADPH
-
isoenzymes 1 and 2
-
r
pyridine-4-aldehyde + NADPH
pyridine-4-alcohol + NADP+
-
isoenzymes 1 and 2
-
r
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
testosterone + NAD+
androstenedione + NADH
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
testosterone + NADP+
androstenedione + NADPH + H+
additional information
?
-
-
human 17beta-hydroxysteroid dehydrogenases are multifunctional enzymes, isozyme 17beta-HSD4 also performs beta-oxidation of branched fatty acids, like pristanic acid, and in bile acid synthesis, e.g. of di- and trihydroxycholestanoic acids, overview
-
-
?
11-hydroxy-androstenedione + NADPH
11beta-hydroxy-testosterone
-
-
-
-
?
11-hydroxy-androstenedione + NADPH
11beta-hydroxy-testosterone
-
-
-
-
?
11-ketoandrostenedione + NADPH
11-ketotestosterone + NADP+
-
-
-
-
?
11-ketoandrostenedione + NADPH
11-ketotestosterone + NADP+
-
-
-
-
?
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
17beta-estradiol + NADP+
estrone + NADPH
-
-
-
r
5alpha-androstane-3alpha,17beta-diol + NADP+
5alpha-androstane-3alpha-ol-17-one + NADPH
-
93% activity compared to testosterone oxidation
-
r
5alpha-androstane-3alpha,17beta-diol + NADP+
5alpha-androstane-3alpha-ol-17-one + NADPH
-
63% activity compared to testosterone oxidation
-
r
5alpha-androstane-3beta,17beta-diol + NADP+
5alpha-androstane-3beta-ol-17-one + NADPH
-
25% activity compared to testosterone oxidation
-
r
5alpha-androstane-3beta,17beta-diol + NADP+
5alpha-androstane-3beta-ol-17-one + NADPH
-
134% activity compared to testosterone oxidation
-
r
5beta-androstane-3alpha,17beta-diol + NADP+
5beta-androstane-3alpha-ol-17-one + NADPH + H+
-
1180% activity compared to testosterone oxidation
-
r
5beta-androstane-3alpha,17beta-diol + NADP+
5beta-androstane-3alpha-ol-17-one + NADPH + H+
-
-
-
r
5beta-dihydrotestosterone + NADP+
5beta-17-oxo-dihydrotestosterone + NADPH
-
-
-
-
?
5beta-dihydrotestosterone + NADP+
5beta-17-oxo-dihydrotestosterone + NADPH
-
isoenzymes 1 and 2
-
r
androst-4-ene-3,17-dione + NADPH
testosterone + NADP+
-
-
-
-
?
androst-4-ene-3,17-dione + NADPH
testosterone + NADP+
-
the enzyme plays a central role in the development of the male phenotype. Mutations that inactivate the enzyme give rise to a rare form of male pseudohermaphroditism, referred to as 17beta-HSD-3 deficiency
-
-
?
androst-4-ene-3,17-dione + NADPH
testosterone + NADP+
-
convertion of the weak androgen androstendione into the potent androgen testosterone
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
the equilibrium state is 92% testosterone to 8% androstenedione
-
-
r
androstenedione + NADPH + H+
testosterone + NADP+
-
the enzyme is involved in biosynthesis of testosterone
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
17beta-HSD3
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
i.e. 4-androsten-17-ol-3-one
-
?
androstenedione + NADPH + H+
testosterone + NADP+
-
17beta-HSD3
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
the two reactions 11beta-HSD1-dehydrogenase, EC 1.1.1.146, and 17beta-HSD3, EC 1.1.1.64, which utilize NADPH are competing for NADPH from the same cofactor pool. 11beta-HSD1-dehydrogenase serves as a NADPH-regenerating system that is tightly coupled in regulating 17beta-HSD3 reaction synthesizing testosterone. A cycle can exist whereby the NADPH produced by 11beta-HSD1 dehydrogenase can drive the reductase activity of 17beta-HSD3 and the NADP+ produced by 17beta-HSD3 and other enzymes involved in testosterone biosynthesis can drive the dehydrogenase activity of 11beta-HSD1
i.e. 4-androsten-17beta-ol-3-one
-
?
dehydroepiandrosterone + NADPH
androst-5-en-3beta,17beta-diol + NADP+
-
-
-
-
?
dehydroepiandrosterone + NADPH
androst-5-en-3beta,17beta-diol + NADP+
-
-
-
-
?
epiandrosterone + NADPH
androstane-3beta,17beta-diol + NADP+
-
-
-
-
?
epiandrosterone + NADPH
androstane-3beta,17beta-diol + NADP+
-
-
-
-
?
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
-
-
-
-
?
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
-
NADP+ is preferred
-
r
testosterone + NAD+
androstenedione + NADH
-
NAD+ shows ess than 10% of the activity with NADP+
-
-
ir
testosterone + NAD+
androstenedione + NADH
-
NAD+ shows 20% of the activity with NADP+
-
-
ir
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
17beta-hydroxysteroid dehydrogenase 3, reduction of androst-4-ene-3,17-dione is preferred
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
17beta-hydroxysteroid dehydrogenase 3, reduction of androst-4-ene-3,17-dione is preferred
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
17beta-hydroxysterod dehydrogenase 3, reduction of androst-4-ene-3,17-dione is preferred
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
17beta-hydroxysterod dehydrogenase 3, reduction of androst-4-ene-3,17-dione is preferred
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
-
-
r
testosterone + NADP+
androst-4-ene-3,17-dione + NADPH + H+
-
rate of oxidation is less than 30% of those for reduction
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
?
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
?
testosterone + NADP+
androstenedione + NADPH + H+
-
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2,4-dihydroxyphenyl)-phenylmethanone
-
(2E)-3-(4-bromophenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
93.3% inhibition at 0.1 mM
(2E)-3-(4-ethylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
89.1% inhibition at 0.1 mM
(2E)-3-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
92.7% inhibition at 0.1 mM
(2E)-3-[4-(methylsulfanyl)phenyl]-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
93.5% inhibition at 0.1 mM
(3,6-dihydropyridin-1(2H)-yl)(1H-indol-2-yl)methanone
crystal structure analysis of enzyme-inhibitor complex
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
(3alpha,5alpha)-3-[(2,5-dimethyl-4-{[2-(trifluoromethyl)phenyl]sulfonyl}piperazin-1-yl)methyl]-3-hydroxyandrostan-17-one
the inhibitor RM-532-105 seems to have difficulties in penetrating inside the testis and is concentrated in the testicular capsule. Therefore it is unable to inhibit the 17bets-HSD3 located inside the testis. At a higher concentration, RM-532-105 significantly decreases the level of testosterone and dihydrotestosterone in rat plasma, in vivo effects of the inhibitor in testis and plasma, detailed overview
(3alpha,5alpha)-3-[[trans-2,5-dimethyl-4-[[2-(trifluoromethyl)-phenyl]sulfonyl]piperazin-1-yl]methyl]-3-hydroxyandrostan-17-one
strong inhibition of isoform 17beta-HSD3 overexpressed in HEK-293 cells
(3R,10S,13S)-3-(Adamantan-1-ylmethyl-butyl-amino)-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
IC50: 80 nM
(3R,10S,13S)-3-[(2-Cyclopentyl-ethyl)-morpholin-4-yl-amino]-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
IC50: 74 nM
(3R,5'R,10S,13S)-4',5'-dibenzyl-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
6.2-19.5% inhibition at 0.0001-0.001 mM
(3R,5'R,10S,13S)-5'-benzyl-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
58.2-90.4% inhibition at 0.0001-0.001 mM
(3R,5'S,10S,13S)-4',5'-dibenzyl-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
25.6-87.3% inhibition at 0.0001-0.001 mM
(3R,5'S,10S,13S)-5'-benzyl-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
18.5-63.2% inhibition at 0.0001-0.001 mM
(3R,5S,5'R,8R,9S,10S,13S,14S)-10,13-dimethyl-5'-(3-methylbutyl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,5'R,8R,9S,10S,13S,14S)-10,13-dimethyl-5'-phenoxytetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,5'R,8R,9S,10S,13S,14S)-4'-benzyl-10,13-dimethyl-5'-(2-methylpropyl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,5'R,8R,9S,10S,13S,14S)-4'-benzyl-10,13-dimethyl-5'-phenoxytetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,5'S,8R,9S,10S,13S,14S)-10,13-dimethyl-5'-(3-methylbutyl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,5'S,8R,9S,10S,13S,14S)-10,13-dimethyl-5'-phenoxytetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,5'S,8R,9S,10S,13S,14S)-4'-benzyl-10,13-dimethyl-5'-phenoxytetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-(2-phenylethyl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-(3-phenylpropyl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-(4-phenylbutyl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-(prop-2-en-1-yl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-(prop-2-yn-1-yl)tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[(4-phenoxyphenyl)methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[(5-phenoxy-1H-1,2,3-triazol-1-yl)methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[(naphthalen-1-yl)methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[(naphthalen-2-yl)methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[2-[4-(trifluoromethyl)phenyl]ethyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[4-(trifluoromethyl)benzene-1-sulfonyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[4-(trifluoromethyl)benzoyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[[2-(trifluoromethyl)phenyl]methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[[3-(trifluoromethyl)phenyl]methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[[4-(trifluoromethoxy)phenyl]methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-4'-[[4-(trifluoromethyl)phenyl]methyl]tetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-3'-benzyl-10,13-dimethyltetradecahydro-2'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidine]-2',17(2H)-dione
strong inhibition of isoform 17beta-HSD3 overexpressed in HEK-293 cells. 44% inhibition at 0.1 microM in homogenized cells
(3R,5S,8R,9S,10S,13S,14S)-4'-benzyl-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-4'-[(4-bromophenyl)methyl]-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-4'-[([1,1'-biphenyl]-4-yl)methyl]-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-4'-[[2,4-bis(trifluoromethyl)phenyl]methyl]-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3R,5S,8R,9S,10S,13S,14S)-4'-[[3,5-bis(trifluoromethyl)phenyl]methyl]-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
-
-
(3S)-3,4-dibenzyl-1-oxa-4-azaspiro[5.5]undecan-2-one
(3S)-3-benzyl-1-oxa-4-azaspiro[5.5]undecan-2-one
(3S)-3-benzyl-4-(prop-2-yn-1-yl)-1-oxa-4-azaspiro[5.5]undecan-2-one
-
-
(3S)-3-benzyl-4-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-1-oxa-4-azaspiro[5.5]undecan-2-one
-
-
(5-methyl-1H-indol-2-yl)(4-propylpiperidin-1-yl)methanone
crystal structure analysis of enzyme-inhibitor complex
(5alpha)-3-hydroxyandrostan-17-one
-
-
(RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
(RS)-3(3'-phenylpropoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
-
IC50: 0.0421 mM
1-(4-hydroxyphenyl)-butan-1-one
-
IC50: 0.08951 mM
1-(4-hydroxyphenyl)-ethanone
-
IC50: 1.70892 mM
1-(4-hydroxyphenyl)-heptan-1-one
-
IC50: 0.0784 mM
1-(4-hydroxyphenyl)-hexan-1-one
-
IC50: 0.01802 mM
1-(4-hydroxyphenyl)-nonan-1-one
-
IC50: 0.00286 mM
1-(4-hydroxyphenyl)-octan-1-one
-
IC50: 0.00652 mM
1-(4-hydroxyphenyl)-pentan-1-one
-
IC50: 0.00497 mM; IC50: 0.06052 mM
1-(4-hydroxyphenyl)-propan-1-one
-
IC50: 0.15056 mM
1-(4-hydroxyphenyl)-undeca-1-one
-
IC50: 0.00755 mM
1-(4-[[(2R)-2-methylpiperidin-1-yl]sulfonyl]phenyl)-1,3-dihydro-2H-pyrrol-2-one
IC50 value in HCT-116 cells engineered to over-express AKR1C3 is 11 nM
1-(4-[[(2R,6S)-2,6-dimethylpiperidin-1-yl]sulfonyl]phenyl)pyrrolidin-2-one
IC50 value in HCT-116 cells engineered to over-express AKR1C3 is 22 nM
1-methyl-3,17-dione-androsta-1,4-diene
-
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
1-[4-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]pyrrolidin-2-one
IC50 value in HCT-116 cells engineered to over-express AKR1C3 is 24 nM
2,5-diphenyl-p-benzoquinone
-
IC50: 0.0027 mM, reduction of androstenedione
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(2-hydroxyphenyl)acetamide
inhibitor is about 1000times more selective for isoform AKR1C3 over AKR1C2, and selectivity is even higher when compared with AKR1C1 and AKR1C4
2-methylcinnamic acid
-
IC50: 0.0064 mM
2-[[(3-hydroxyphenyl)carbonyl]amino]-4,5-dimethoxybenzoic acid
-
2-[[(3-hydroxyphenyl)carbonyl]amino]-5-nitrobenzoic acid
-
3,4,5-trimethoxycinnamic acid
-
IC50: 0.049 mM
3-((4-nitronaphthalen-1-yl)amino)benzoic acid
inhibitor nanomolar potency and selective inhibition of isoform AKR1C3 but also acts as an androgen receptor antagonist. It inhibits 5alpha-dihydrotestosterone stimulated androgen receptor reporter gene activity with an IC50 value of 4.7 microM and produces a concentration dependent reduction in androgen receptor levels in prostate cancer cells
3-(17'-oxo-5'alpha-androstan-3'alpha-oxy)propanoic acid
-
0.003 mM, 48% inhibition
3-(4-Bromo-2-methyl-benzyl)-7-hydroxy-chroman-4-one
-
IC50: 0.0083 mM, reduction of androstenedione
3-(4-Chloro-2-methyl-benzyl)-7-hydroxy-chroman-4-one
-
IC50: 0.0018 mM, reduction of androstenedione
3-(4-Fluoro-2-methyl-benzyl)-7-hydroxy-chroman-4-one
-
IC50: 0.007 mM, reduction of androstenedione
3-coumaric acid
-
34% inhibition at 0.05 mM
3-cyclohexyl-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
-
3-cyclohexylmethyl-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
-
3-cyclohexylpropanoic acid
-
weak inhibition, IC50: 0.1 mM, above
3-hexyl-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
-
3-hydroxy-10,13-dimethyl-3-octyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
-
3-hydroxy-10,13-dimethyl-3-phenethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
-
3-hydroxy-10,13-dimethyl-3-phenyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
-
-
3-pentyl-2-[[(pyridin-2-yl)methyl]sulfanyl]-7-(pyrrolidine-1-carbonyl)quinazolin-4(3H)-one
crystal structure analysis of enzyme-inhibitor complex
3-phenoxybenzoic acid
inhibitor carboxylic acid binds to the oxyanion site, in which the carboxylate group very closely overlays the acetate molecule found in other AKR1C3 structures and forms hydrogen bonds to the enzyme catalytic residues His117 and Tyr55, as well as to a conserved water network located in and near the SP3 subpocket. The 3-phenoxy ring extends into the SP1 subpocket and makes van der Waals contacts with the aromatic residues Phe306, Phe311 and Tyr319 that line the pocket
3-trifluoromethylcinnamic acid
-
IC50: 0.043 mM
3-[(4-nitrophenyl)amino]benzoic acid
94fold selectivity for the inhibition of isoform AKR1C3 over AKR1C2
3-[[4-(methoxymethyl)phenyl]amino]benzoic acid
360fold selectivity for the inhibition of isoform AKR1C3 over AKR1C2
3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid
3a-phenyl-2,3,3a,4-tetrahydro-1H-pyrrolo[1,2-a]benzimidazol-1-one
inhibitor shows 17fold and 30fold selectivity against isoforms AKR1C2 and AKR1C1, respectively, and much higher selectivity against AKR1C4
3alpha,3beta-O-(1'-oxo-1',3'-propanediyloxy)-5alpha-androstan-17-one
-
0.003 mM, 53% inhibition
3alpha-(2'-hydroxypropanoxy)-5alpha-androstan-17-one
-
0.003 mM, 89% inhibition
3alpha-(3'-bromopropanoxy)-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition
3alpha-(3'-hydroxypropanoxy)-5alpha-androstan-17-one
-
0.003 mM, 86% inhibition
3alpha-(prop-2'-enoxy)-5alpha-androstan-17-one
-
0.003 mM, 95% inhibition
3alpha-ethoxy-3beta-(phenylmethyl)-5alpha-androstan-17-one
-
0.003 mM, 92% inhibition, IC50: 352 nM
3alpha-ethoxy-5alpha-androstan-17-one
-
0.003 mM, 95% inhibition
3alpha-hexanoxy-3beta-(phenylmethyl)-5alpha-androstan-17-one
-
0.003 mM, 28% inhibition
3alpha-hexanoxy-5alpha-androstan-17-one
-
0.003 mM, 92% inhibition
3alpha-hydroxy-3'-phenyl-5alpha-androstan-17-one
-
0.003 mM, 95% inhibition, IC50: 81 nM
3alpha-hydroxy-3beta-(3'-hydroxypropyl)-5alpha-androstan-17-one
-
0.003 mM, 74% inhibition
3alpha-hydroxy-3beta-(prop-2'-enyl)-5alpha-androstan-17-one
-
0.003 mM, 76% inhibition
3alpha-hydroxy-3beta-methyl-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition
3alpha-hydroxy-3beta-octyl-5alpha-androstan-17-one
-
0.003 mM, 92% inhibition, IC50: 147 nM
3alpha-hydroxy-3beta-phenylethyl-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition, IC50: 99 nM
3alpha-hydroxy-3beta-phenylmethyl-5alpha-androstan-17-one
-
0.003 mM, 94% inhibition, IC50: 57 nM
3alpha-hydroxy-3beta-phenylpropyl-5alpha-androstan-17-one
-
0.003 mM, 97% inhibition
3alpha-hydroxy-3beta-propyl-5alpha-androstan-17-one
-
0.003 mM, 94% inhibition, IC50: 67 nM
3alpha-hydroxy-3beta-vinyl-5alpha-androstan-17-one
-
0.003 mM, 94% inhibition
3alpha-methoxy-3beta-(2'-phenylethyl)-5alpha-androstan-17-one
-
0.003 mM, 95% inhibition, IC50: 73 nM
3alpha-methoxy-3beta-(phenylmethyl)-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition, IC50: 154 nM
3alpha-methoxy-5alpha-androstan-17-one
-
0.003 mM, 94% inhibition
3alpha-O-(spirotetrahydrofuran-2-yl)-5alpha-androstan-17-one
-
0.003 mM, 94% inhibition
3alpha-propanoxy-3beta-(phenylmethyl)-5alpha-androstan-17-one
-
0.003 mM, 87% inhibition
3alpha-propanoxy-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition
3b-Methyl-5a-androstan-3a-ol-17-on
-
-
3beta,3alpha-O-(1'-oxo-1',3'-propanediyloxy)-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition
3beta-(2'-cyclohexylethyl)-3alpha-methoxy-5alpha-androstan-17-one
-
0.003 mM, 88% inhibition, IC50: 354 nM
3beta-cyclohexyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 95% inhibition, IC50: 97 nM
3beta-cyclohexylethyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition, IC50: 60 nM
3beta-cyclohexylethyl-androsterone
-
IC50: 60 nM
3beta-cyclohexylmethyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 95% inhibition, IC50: 87 nM
3beta-dodecyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 77% inhibition
3beta-hydroxy-3alpha-(3'-hydroxypropyl)-5alpha-androstan-17-one
-
0.003 mM, 17% inhibition
3beta-hydroxy-3alpha-(prop-2'-enyl)-5alpha-androstan-17-one
-
0.003 mM, 36% inhibition
3beta-hydroxy-3alpha-methyl-5alpha-androstan-17-one
-
0.003 mM, 16% inhibition
3beta-hydroxy-3alpha-phenyl-5alpha-androstan-17-one
-
0.003 mM, 39% inhibition
3beta-hydroxy-3alpha-phenylmethyl-5alpha-androstan-17-one
-
0.003 mM, 39% inhibition
3beta-hydroxy-3alpha-propyl-5alpha-androstan-17-one
-
0.003 mM, 33% inhibition
3beta-n-butyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 92% inhibition, IC50: 116 nM
3beta-n-hexyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 95% inhibition, IC50: 100 nM
3beta-phenylmethyl-androsterone
-
IC50: 57 nM
3beta-propyl-androsterone
-
IC50: 67 nM
3beta-s-butyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 90% inhibition, IC50: 73 nM
3beta-sec-butyl-androsterone
-
IC50: 73 nM
3beta-tert-butyl-3alpha-hydroxy-5alpha-androstan-17-one
-
0.003 mM, 93% inhibition, IC50: 142 nM
4-chloro-N-[(4-chlorophenyl)methyl]-5-nitro-1H-pyrazole-3-carboxamide
crystal structure analysis of enzyme-inhibitor complex
4-nitro-2-([4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl)phenol
crystal structure analysis of enzyme-inhibitor complex
5-(3-bromo-4-hydroxybenzyl)-3-(4-methoxyphenyl)-1,3-thiazol-2-one
5-(3-bromo-4-hydroxybenzylidene)-3-(4-fluorophenyl)-2-thioxo-1,3-oxazolidin-4-one
strong inhibitory activity on isoform 3beta-HSD3
5-(3-bromo-4-hydroxybenzylidene)-3-(4-methoxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
compound demonstrates significant selectivity for isoform 17beta-hydroxysteroid dehydrogenase type 3 over the related isoenzymes and nuclear receptors. IC50 value 14 nM in cell-based assay
5-(3-bromo-4-hydroxybenzylidene)-3-(4-methylphenyl)-2-thioxo-1,3-oxazolidin-4-one
strong inhibitory activity on isoform 3beta-HSD3
5-(3-chloro-5-fluoro-4-hydroxybenzylidene)-3-(4-methoxyphenyl)-2-thioxo-1,3-oxazolidin-4-one
strong inhibitory activity on isoform 3beta-HSD3
5-(3-fluoro-4-hydroxybenzylidene)-3-(4-methoxyphenyl)-2-tioxo-1,3-oxazolidin-4-one
strong inhibitory activity on isoform 3beta-HSD3
5-(benzenesulfonyl)-2-nitrophenol
crystal structure analysis of enzyme-inhibitor complex
5-androstene-3,17-dione
-
-
5-bromo-2-[[(3-hydroxyphenyl)carbonyl]amino]benzoic acid
-
5-chloro-2-[[(3-hydroxyphenyl)carbonyl]amino]benzoic acid
-
5-[3,5-dichloro-4-(phosphonoxy)benzylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-oxazolidin-4-one
Biochanin A
-
IC50: 0.0108 mM, reduction of androstenedione
bis(2-butoxyethyl) phthalate
caffeic acid
-
18% inhibition at 0.05 mM
Cinnamic acid
-
IC50: 0.050 mM
clomiphene
-
IC50: 0.0762 mM
coumarin-3-carboxylic acid
-
30% inhibition at 0.05 mM
CuCl2
-
10 mM, 40% inhibition
Cyclopropanecarboxylic acid ((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-octyl-amide
-
IC50: 57 nM
Cyclopropanecarboxylic acid cyclohexylmethyl-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-amide
-
IC50: 85 nM
FeCl3
-
10 mM, 54% inhibition
heptanoic acid (1-{1-[(3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-ylmethyl)-carbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethyl)-amide
-
IC50: 227 nM
methyl (2R)-2-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-4-methylpentanoate
-
-
methyl (2R)-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl](phenoxy)acetate
-
-
methyl (2S)-2-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-4-methylpentanoate
-
-
methyl (2S)-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl](phenoxy)acetate
-
-
methyl [(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]acetate
-
-
N-Adamantan-1-ylmethyl-N-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-butyramide
-
IC50: 35-57 nM
p-chloromercuribenzoate
-
10 mM, strong inhibition, 5% residual activity is reversed to 65% activity by either 1 mM glutathione or cysteine
Pb(NO3)2
-
10 mM, 30% inhibition
phenyl-p-benzoquinone
-
IC50: 0.0057 mM, reduction of androstenedione
Sodium amytal
-
10 mM, 25% inhibition
Sodium cyanide
-
10 mM, progressive and marked inhibition
STX2171
ability to penetrate the cell. Lack of inhibition of 17beta-HSD2 (the enzyme that catalyzes the opposite reaction to that of 17beta-HSD3, which is the oxidation of active testosterone to inactive androstenedione)
tamoxifen
-
IC50: 0.098 mM, time-dependent and irreversible
testosterone
-
1 mM, 62.8% inhibition of androstendione reduction
ZnCl2
-
10 mM, 90% inhibition
(+)-gossypol
-
-
(-)-gossypol
-
-
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
-
-
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
-
48.8-92.0% inhibition at 0.0001-0.001 mM
(3S)-3,4-dibenzyl-1-oxa-4-azaspiro[5.5]undecan-2-one
-
-
(3S)-3,4-dibenzyl-1-oxa-4-azaspiro[5.5]undecan-2-one
-
47.3-92.1% inhibition at 0.0001-0.001 mM
(3S)-3-benzyl-1-oxa-4-azaspiro[5.5]undecan-2-one
-
-
(3S)-3-benzyl-1-oxa-4-azaspiro[5.5]undecan-2-one
-
24.2-24.3% inhibition at 0.0001-0.001 mM
(RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
-
IC50: 0.0091 mM, reduction of androstenedione
(RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
-
IC50: 0.00915 mM
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
-
-
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
-
3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid
250fold selectivity for the inhibition of isoform AKR1C3 over AKR1C2
3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid
in complex with AKR1C3. Compound adopts a similar binding orientation as flufenamic acid, however, its phenylamino ring projects deeper into a subpocket and confers selectivity over the other AKR1C isoforms
4-Methylumbelliferone
-
IC50: 0.0009 mM, reduction of androstenedione
4-Methylumbelliferone
-
IC50: 0.0019 mM
5-(3-bromo-4-hydroxybenzyl)-3-(4-methoxyphenyl)-1,3-thiazol-2-one
starting compound for high-throughput screening. IC50 value 570 nM in cell-based assay
5-(3-bromo-4-hydroxybenzyl)-3-(4-methoxyphenyl)-1,3-thiazol-2-one
selective non-steroidal 17beta-HSD3 inhibitor that does not show any undesired inhibition of estrogen biosynthesis and does not possess the transcriptional activity against any of these nuclear receptors
5-[3,5-dichloro-4-(phosphonoxy)benzylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-oxazolidin-4-one
strong inhibitory activity on isoform 3beta-HSD3
5-[3,5-dichloro-4-(phosphonoxy)benzylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-oxazolidin-4-one
-
strong inhibitory activity on isoform 3beta-HSD3. When administered orally at a high dose of 100 mg/kg, compound shows approximately two times more potent testosterone-lowering effect against a positive control in the luteinizing hormone-releasing hormone-induced T production assay. The T-lowering effect continues at ca 10% level of control over 4 h after administration
7-hydroxyflavone
-
IC50: 0.009 mM, reduction of androstenedione
7-hydroxyflavone
-
IC50: 0.06698 mM
baicalein
-
IC50: 0.0093 mM, reduction of androstenedione
baicalein
-
IC50: 0.18592 mM
bis(2-butoxyethyl) phthalate
potent inhibitor of testis 17beta-hydroxysteroid dehydrogenase type 3, additionally inhibits 3beta-hydroxysteriod dehydrogenase
bis(2-butoxyethyl) phthalate
-
potent inhibitor of testis 17beta-hydroxysteroid dehydrogenase type 3, additionally inhibits 3beta-hydroxysteriod dehydrogenase
canadine
-
-
corydaline
-
-
corypalmine
-
-
dicyclohexyl phthalate
potent inhibitor of testis 17beta-hydroxysteroid dehydrogenase type 3, additionally inhibits 3beta-hydroxysteriod dehydrogenase
dicyclohexyl phthalate
-
potent inhibitor of testis 17beta-hydroxysteroid dehydrogenase type 3, additionally inhibits 3beta-hydroxysteriod dehydrogenase
RM-532-105
-
RM-532-105
the inhibitor RM-532-105 seems to have difficulty penetrating the testis and was found to be concentrated in the testicular capsule, therefore unable to inhibit the 17beta-HSD3 located inside the testis
scoulerine
-
-
Stylopine
-
-
Stylopine
the most potent inhibitor among the tested compounds that exhibited moderate selectivity towards AKR1C3 versus AKR1C1, EC 1.1.1.62. Stylopine significantly inhibits the AKR1C3-mediated reduction of daunorubicin in intact cells without considerable cytotoxic effects
tetrahydrocolumbamine
-
-
tetrahydroplamatine
-
-
-
umbelliferone
-
IC50: 0.0014 mM, reduction of androstenedione
umbelliferone
-
IC50: 0.0014 mM
additional information
crystal structures of complexes of 17beta-HSD5 with structurally diverse inhibitors derived from high-throughput inhibitor screening, overview. Analysis of interactions between 17beta-HSD5 and inhibitors at the atomic level which enable structure-based drug design for anti-CRPC therapy
-
additional information
-
design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3, structure-activity relationship study, overview
-
additional information
nineteen isoquinoline alkaloids were examined for their ability to inhibit a recombinant AKR1C3 enzyme
-
additional information
activity of 17beta-HSD is significantly decreased in metyrapone-induced corticosterone-deficient rat Leydig cells compared to control, whereas simultaneous administration of corticosterone partially prevented this and maintained the activity at near normal levels
-
additional information
-
synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00113 - 0.01093
(+)-gossypol
0.00036 - 0.00343
(-)-gossypol
0.0136
(2E)-3-(4-bromophenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0136
(2E)-3-(4-ethylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0134
(2E)-3-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0058
(2E)-3-[4-(methylsulfanyl)phenyl]-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0028
(3,6-dihydropyridin-1(2H)-yl)(1H-indol-2-yl)methanone
Homo sapiens
pH 6.0, 22°C
0.000014
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
Rattus norvegicus
-
pH and temperature not specified in the publication
0.000006
(3alpha,5alpha)-3-[[trans-2,5-dimethyl-4-[[2-(trifluoromethyl)-phenyl]sulfonyl]piperazin-1-yl]methyl]-3-hydroxyandrostan-17-one
Homo sapiens
assay uses homogenized cells, pH not specified in the publication, temperature not specified in the publication
0.00008
(3R,10S,13S)-3-(Adamantan-1-ylmethyl-butyl-amino)-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
Homo sapiens
-
IC50: 80 nM
0.000074
(3R,10S,13S)-3-[(2-Cyclopentyl-ethyl)-morpholin-4-yl-amino]-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
Homo sapiens
-
IC50: 74 nM
0.000048
(3R,5'S,10S,13S)-4',5'-dibenzyl-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
Rattus norvegicus
-
pH and temperature not specified in the publication
0.000022
(3R,5'S,10S,13S)-5'-benzyl-10,13-dimethyltetradecahydro-6'H-spiro[cyclopenta[a]phenanthrene-3,2'-[1,4]oxazinane]-6',17(2H)-dione
Rattus norvegicus
-
pH and temperature not specified in the publication
0.000037
(5-methyl-1H-indol-2-yl)(4-propylpiperidin-1-yl)methanone
Homo sapiens
pH 6.0, 22°C
0.0091 - 0.00915
(RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
0.0421
(RS)-3(3'-phenylpropoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
Homo sapiens
-
IC50: 0.0421 mM
0.08951
1-(4-hydroxyphenyl)-butan-1-one
Rattus norvegicus
-
IC50: 0.08951 mM
1.70892
1-(4-hydroxyphenyl)-ethanone
Rattus norvegicus
-
IC50: 1.70892 mM
0.0784
1-(4-hydroxyphenyl)-heptan-1-one
Rattus norvegicus
-
IC50: 0.0784 mM
0.01802
1-(4-hydroxyphenyl)-hexan-1-one
Rattus norvegicus
-
IC50: 0.01802 mM
0.00286
1-(4-hydroxyphenyl)-nonan-1-one
Rattus norvegicus
-
IC50: 0.00286 mM
0.00652
1-(4-hydroxyphenyl)-octan-1-one
Rattus norvegicus
-
IC50: 0.00652 mM
0.00497 - 0.06052
1-(4-hydroxyphenyl)-pentan-1-one
0.15056
1-(4-hydroxyphenyl)-propan-1-one
Rattus norvegicus
-
IC50: 0.15056 mM
0.00755
1-(4-hydroxyphenyl)-undeca-1-one
Rattus norvegicus
-
IC50: 0.00755 mM
0.000094
1-(4-[[(2R)-2-methylpiperidin-1-yl]sulfonyl]phenyl)-1,3-dihydro-2H-pyrrol-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000056
1-(4-[[(2R,6S)-2,6-dimethylpiperidin-1-yl]sulfonyl]phenyl)pyrrolidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000052
1-[4-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]pyrrolidin-2-one
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0027
2,5-diphenyl-p-benzoquinone
Homo sapiens
-
IC50: 0.0027 mM, reduction of androstenedione
0.000213
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(2-hydroxyphenyl)acetamide
Homo sapiens
pH 7.0, temperature not specified in the publication
0.0064
2-methylcinnamic acid
Homo sapiens
-
IC50: 0.0064 mM
0.0052
2-[[(3-hydroxyphenyl)carbonyl]amino]-4,5-dimethoxybenzoic acid
Homo sapiens
pH 7.0, temperature not specified in the publication
0.00084
2-[[(3-hydroxyphenyl)carbonyl]amino]-5-nitrobenzoic acid
Homo sapiens
pH 7.0, temperature not specified in the publication
0.049
3,4,5-trimethoxycinnamic acid
Homo sapiens
-
IC50: 0.049 mM
0.08
3-((4-nitronaphthalen-1-yl)amino)benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0083
3-(4-Bromo-2-methyl-benzyl)-7-hydroxy-chroman-4-one
Homo sapiens
-
IC50: 0.0083 mM, reduction of androstenedione
0.0018
3-(4-Chloro-2-methyl-benzyl)-7-hydroxy-chroman-4-one
Homo sapiens
-
IC50: 0.0018 mM, reduction of androstenedione
0.007
3-(4-Fluoro-2-methyl-benzyl)-7-hydroxy-chroman-4-one
Homo sapiens
-
IC50: 0.007 mM, reduction of androstenedione
0.1
3-cyclohexylpropanoic acid
Homo sapiens
-
weak inhibition, IC50: 0.1 mM, above
0.0029
3-pentyl-2-[[(pyridin-2-yl)methyl]sulfanyl]-7-(pyrrolidine-1-carbonyl)quinazolin-4(3H)-one
Homo sapiens
pH 6.0, 22°C
0.043
3-trifluoromethylcinnamic acid
Homo sapiens
-
IC50: 0.043 mM
0.000036
3-[(4-nitrophenyl)amino]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000054
3-[[4-(methoxymethyl)phenyl]amino]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000062
3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00546
3a-phenyl-2,3,3a,4-tetrahydro-1H-pyrrolo[1,2-a]benzimidazol-1-one
Homo sapiens
pH 7.0, temperature not specified in the publication
0.000352
3alpha-ethoxy-3beta-(phenylmethyl)-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 92% inhibition, IC50: 352 nM
0.000081
3alpha-hydroxy-3'-phenyl-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 95% inhibition, IC50: 81 nM
0.000147
3alpha-hydroxy-3beta-octyl-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 92% inhibition, IC50: 147 nM
0.000099
3alpha-hydroxy-3beta-phenylethyl-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 93% inhibition, IC50: 99 nM
0.000057
3alpha-hydroxy-3beta-phenylmethyl-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 94% inhibition, IC50: 57 nM
0.000067
3alpha-hydroxy-3beta-propyl-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 94% inhibition, IC50: 67 nM
0.000073
3alpha-methoxy-3beta-(2'-phenylethyl)-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 95% inhibition, IC50: 73 nM
0.000154
3alpha-methoxy-3beta-(phenylmethyl)-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 93% inhibition, IC50: 154 nM
0.000354
3beta-(2'-cyclohexylethyl)-3alpha-methoxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 88% inhibition, IC50: 354 nM
0.000097
3beta-cyclohexyl-3alpha-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 95% inhibition, IC50: 97 nM
0.00006
3beta-cyclohexylethyl-3alpha-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 93% inhibition, IC50: 60 nM
0.00006
3beta-cyclohexylethyl-androsterone
Homo sapiens
-
IC50: 60 nM
0.000087
3beta-cyclohexylmethyl-3alpha-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 95% inhibition, IC50: 87 nM
0.000116
3beta-n-butyl-3alpha-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 92% inhibition, IC50: 116 nM
0.0001
3beta-n-hexyl-3alpha-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 95% inhibition, IC50: 100 nM
0.000057
3beta-phenylmethyl-androsterone
Homo sapiens
-
IC50: 57 nM
0.000067
3beta-propyl-androsterone
Homo sapiens
-
IC50: 67 nM
0.000073
3beta-s-butyl-3alpha-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 90% inhibition, IC50: 73 nM
0.000073
3beta-sec-butyl-androsterone
Homo sapiens
-
IC50: 73 nM
0.000142
3beta-tert-butyl-3alpha-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
0.003 mM, 93% inhibition, IC50: 142 nM
0.0026
4-chloro-N-[(4-chlorophenyl)methyl]-5-nitro-1H-pyrazole-3-carboxamide
Homo sapiens
pH 6.0, 22°C
0.0009 - 0.0019
4-Methylumbelliferone
0.00049
4-nitro-2-([4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl)phenol
Homo sapiens
pH 6.0, 22°C
0.000002
5-(3-bromo-4-hydroxybenzylidene)-3-(4-fluorophenyl)-2-thioxo-1,3-oxazolidin-4-one
Homo sapiens
cell-based assay, pH not specified in the publication, temperature not specified in the publication
0.000002
5-(3-bromo-4-hydroxybenzylidene)-3-(4-methylphenyl)-2-thioxo-1,3-oxazolidin-4-one
Homo sapiens
cell-based assay, pH not specified in the publication, temperature not specified in the publication
0.000002
5-(3-chloro-5-fluoro-4-hydroxybenzylidene)-3-(4-methoxyphenyl)-2-thioxo-1,3-oxazolidin-4-one
Homo sapiens
cell-based assay, pH not specified in the publication, temperature not specified in the publication
0.000002
5-(3-fluoro-4-hydroxybenzylidene)-3-(4-methoxyphenyl)-2-tioxo-1,3-oxazolidin-4-one
Homo sapiens
cell-based assay, pH not specified in the publication, temperature not specified in the publication
0.00029
5-(benzenesulfonyl)-2-nitrophenol
Homo sapiens
pH 6.0, 22°C
0.0019
5-bromo-2-[[(3-hydroxyphenyl)carbonyl]amino]benzoic acid
Homo sapiens
pH 7.0, temperature not specified in the publication
0.0022
5-chloro-2-[[(3-hydroxyphenyl)carbonyl]amino]benzoic acid
Homo sapiens
pH 7.0, temperature not specified in the publication
0.000001
5-[3,5-dichloro-4-(phosphonoxy)benzylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-oxazolidin-4-one
Homo sapiens
cell-based assay, pH not specified in the publication, temperature not specified in the publication
0.009 - 0.06698
7-hydroxyflavone
0.0093 - 0.18592
baicalein
0.0108
Biochanin A
Homo sapiens
-
IC50: 0.0108 mM, reduction of androstenedione
0.0233 - 0.0825
bis(2-butoxyethyl) phthalate
0.05
Cinnamic acid
Homo sapiens
-
IC50: 0.050 mM
0.0762
clomiphene
Homo sapiens
-
IC50: 0.0762 mM
0.000057
Cyclopropanecarboxylic acid ((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-octyl-amide
Homo sapiens
-
IC50: 57 nM
0.000085
Cyclopropanecarboxylic acid cyclohexylmethyl-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-amide
Homo sapiens
-
IC50: 85 nM
0.0082 - 0.09
dicyclohexyl phthalate
0.000227
heptanoic acid (1-{1-[(3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-ylmethyl)-carbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethyl)-amide
Homo sapiens
-
IC50: 227 nM
0.00046 - 0.0037
indomethacin
0.000035 - 0.000057
N-Adamantan-1-ylmethyl-N-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-butyramide
Homo sapiens
-
IC50: 35-57 nM
0.0057
phenyl-p-benzoquinone
Homo sapiens
-
IC50: 0.0057 mM, reduction of androstenedione
0.000383
STX-2171
Homo sapiens
-
at 37°C
0.000201
STX-2622
Homo sapiens
-
at 37°C
0.000441
STX-2624
Homo sapiens
-
at 37°C
0.0002
STX2171
Homo sapiens
pH and temperature not specified in the publication
0.0009 - 0.0077
Stylopine
0.098
tamoxifen
Homo sapiens
-
IC50: 0.098 mM, time-dependent and irreversible
0.00113
(+)-gossypol
Homo sapiens
-
in PBS buffer, pH 7.2
0.01093
(+)-gossypol
Rattus norvegicus
-
in PBS buffer, pH 7.2
0.00036
(-)-gossypol
Homo sapiens
-
in PBS buffer, pH 7.2
0.00343
(-)-gossypol
Rattus norvegicus
-
in PBS buffer, pH 7.2
0.0091
(RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
Homo sapiens
-
IC50: 0.0091 mM, reduction of androstenedione
0.00915
(RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione
Homo sapiens
-
IC50: 0.00915 mM
0.00497
1-(4-hydroxyphenyl)-pentan-1-one
Rattus norvegicus
-
IC50: 0.00497 mM
0.06052
1-(4-hydroxyphenyl)-pentan-1-one
Rattus norvegicus
-
IC50: 0.06052 mM
0.0009
4-Methylumbelliferone
Homo sapiens
-
IC50: 0.0009 mM, reduction of androstenedione
0.0019
4-Methylumbelliferone
Homo sapiens
-
IC50: 0.0019 mM
0.009
7-hydroxyflavone
Homo sapiens
-
IC50: 0.009 mM, reduction of androstenedione
0.06698
7-hydroxyflavone
Rattus norvegicus
-
IC50: 0.06698 mM
0.0093
baicalein
Homo sapiens
-
IC50: 0.0093 mM, reduction of androstenedione
0.18592
baicalein
Rattus norvegicus
-
IC50: 0.18592 mM
0.0233
bis(2-butoxyethyl) phthalate
Homo sapiens
isoform 17beta-hydroxysteroid dehydrogenase type 3 , pH 7.4, 37°C
0.0302
bis(2-butoxyethyl) phthalate
Rattus norvegicus
-
isoform 17beta-hydroxysteroid dehydrogenase type 3 , pH 7.4, 37°C
0.0503
bis(2-butoxyethyl) phthalate
Homo sapiens
isoform 3beta-hydroxysteriod dehydrogenase , pH 7.4, 37°C
0.0825
bis(2-butoxyethyl) phthalate
Rattus norvegicus
-
isoform 3beta-hydroxysteriod dehydrogenase , pH 7.4, 37°C
0.0122
canadine
Homo sapiens
pH 7.4, 37°C, determined with the oracin to dihydrooracin assay
0.029
canadine
Homo sapiens
pH 7.4, 37°C, determined with the reduction of androstenedione to testosterone assay
0.0082
dicyclohexyl phthalate
Homo sapiens
isoform 17beta-hydroxysteroid dehydrogenase type 3, pH 7.4, 37°C
0.0247
dicyclohexyl phthalate
Rattus norvegicus
-
isoform 3beta-hydroxysteriod dehydrogenase, pH 7.4, 37°C
0.0255
dicyclohexyl phthalate
Homo sapiens
isoform 3beta-hydroxysteriod dehydrogenase, pH 7.4, 37°C
0.09
dicyclohexyl phthalate
Rattus norvegicus
-
isoform 17beta-hydroxysteroid dehydrogenase type 3, pH 7.4, 37°C
0.00046
indomethacin
Homo sapiens
pH 7.4, 37°C, determined with the oracin to dihydrooracin assay
0.0037
indomethacin
Homo sapiens
pH 7.4, 37°C, determined with the reduction of androstenedione to testosterone assay
0.0009
Stylopine
Homo sapiens
pH 7.4, 37°C, determined with the oracin to dihydrooracin assay
0.0077
Stylopine
Homo sapiens
pH 7.4, 37°C, determined with the reduction of androstenedione to testosterone assay
0.0014
umbelliferone
Homo sapiens
-
IC50: 0.0014 mM
0.0014
umbelliferone
Homo sapiens
-
IC50: 0.0014 mM, reduction of androstenedione
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Hara, A.; Nakayama, T.; Nakagawa, M.; Inoue, Y.; Tanabe, H.; Sawada, H.
Kinetic and stereochemical studies on reaction mechanism of mouse liver 17beta-hydroxysteroid dehydrogenases
J. Biochem.
102
1585-1592
1987
Mus musculus
brenda
Villee, C.A.; Spencer, J.M.
Some properties of the pyridine nucleotide-specific 17beta-hydroxy steroid dehydrogenases of guinea pig liver
J. Biol. Chem.
235
3615-3619
1960
Cavia porcellus
brenda
Andersson, S.; Geissler, W.M.; Wu, L.; Davis, D.L.; Grumbach, M.M.; New, M.I.; Schwarz, H.P.; Blethen, S.L.; Mendoca.B.B.; Bloise, W.; Witchel, S.F.; Cutler, G.B.; Griffin, J.E.; Wilson, J.D.; Russell, D.W.
Molecular genetics and pathophysiology of 17beta-hydroxysteroid dehydrogenase 3 deficiency
J. Clin. Endocrinol.
81
130-136
1996
Homo sapiens
brenda
Baker, M.E.
Unusual evolution of 11beta- and 17beta-hydroxysteroid dehydrogenases
BioEssays
18
63-70
1995
Homo sapiens
brenda
Geissler, W.M.; Davis, D.L.; Wu, L.; Bradshaw, K.D.; Patel, S.; Mendoca, B.B.; Elliston, K.O.; Wilson, J.D.; Russell, D.W.; Andersson, S.
Male pseudohermaphroditism caused by mutations of testicular 17beta-hydroxysteroid dehydrogenase 3
Nature Genet.
7
34-39
1994
Homo sapiens
brenda
Inano, H.; Tamaoki, B.
Testicular 17beta-hydroxysteroid dehydrogenas: molecular properties and reaction mechanism
Steroids
48
1-26
1986
Oryctolagus cuniculus, Ovis aries, Rattus norvegicus, Sus scrofa
brenda
Hara, A.; Hayashibara, M.; Nakayama, T.; Hasabe, K.; Usui, s.; Sawada, H.
Guinea-pig liver testosterone 17beta-dehydrogenase (NADP+) and aldehyde reductase exhibit benzene dihydrodiol dehydrogenase activity
Biochem. J.
225
177-181
1985
Cavia porcellus
brenda
Inano, H.; Tamaoki, B.; Hamana, K.; Nakagawa, H.
Amino acid composition and immunochemical properties of porcine testicular 17beta-hydroxysteroid dehydrogenase
J. Steroid Biochem.
13
287-295
1980
Sus scrofa
brenda
Kageura, E.; Toki, S.
Purification and properties of a new testosterone 17beta-dehydrogenase (NADP+) from guinea-pig liver
Biochem. J.
163
401-407
1977
Cavia porcellus
brenda
Inano, H.; Tamaoki, B.
Relationship between steroids and pyridine nucleotides in the oxido-reduction catalyzed by the 17beta-hydroxysteroid dehydrogenase purified from the porcine testicular microsomal fraction
Eur. J. Biochem.
53
319-326
1975
Sus scrofa
brenda
Tamaoki, B-i.; Inano, H.
Testicular 17beta-hydroxysteroid dehydrogenase: its distribution, purification and properties
J. Steroid Biochem.
6
361-363
1975
Rattus norvegicus, Sus scrofa
brenda
Inano, H.; Tamaoki, B.
Purificatition and properties of NADP-dependent 17beta-hydroxysteoid dehydrogenase solubilized from porcine-testicular microsomal fraction
Eur. J. Biochem.
44
13-23
1974
Sus scrofa
brenda
Oshima, H.; Ochiai, K.
On testicular 17beta-hydroxysteroid oxidoreductase product activation of testosterone formation from androstendione in vitro
Biochim. Biophys. Acta
306
227-236
1973
Oryctolagus cuniculus, Homo sapiens
brenda
Endahl, G.L.; Kochakian, C.D.; Hamm, D.
Separation of a triphosphopyridine nucleotide-specific from a diphosphopyridine nucleotide-specific 17beta-hydroxy-(testosterone)dehydrogenase of guinea-pig liver
J. Biol. Chem.
235
2792-2796
1960
Cavia porcellus
brenda
Khan, N.; Sharma, K.K.; Andersson, S.; Auchus, R.J.
Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells
Arch. Biochem. Biophys.
429
50-59
2004
Homo sapiens
brenda
McKeever, B.M.; Hawkins, B.K.; Geissler, W.M.; Wu, L.; Sheridan, R.P.; Mosley, R.T.; Andersson, S.
Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics
Biochim. Biophys. Acta
1601
29-37
2002
Homo sapiens
brenda
Poirier, D.
Inhibitors of 17beta-hydroxysteroid dehydrogenases
Curr. Med. Chem.
10
453-477
2003
Canis lupus familiaris, Homo sapiens, Rattus norvegicus
brenda
le Lain, R.; Barrell, K.J.; Saeed, G.S.; Nicholls, P.J.; Simons, C.; Kirby, A.; Smith, H.J.
Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme
J. Enzyme Inhib. Med. Chem.
17
93-100
2002
Homo sapiens
brenda
Lota, R.K.; Dhanani, S.; Owen, C.P.; Ahmed, S.
Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3)
Bioorg. Med. Chem. Lett.
16
4519-4522
2006
Rattus norvegicus
brenda
Tchedam Ngatcha, B.; Luu-The, V.; Labrie, F.; Poirier, D.
Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship
J. Med. Chem.
48
5257-5268
2005
Homo sapiens
brenda
Mindnich, R.; Haller, F.; Halbach, F.; Moeller, G.; Hrabe de Angelis, M.; Adamski, J.
Androgen metabolism via 17beta-hydroxysteroid dehydrogenase type 3 in mammalian and non-mammalian vertebrates: comparison of the human and the zebrafish enzyme
J. Mol. Endocrinol.
35
305-316
2005
Danio rerio, Homo sapiens
brenda
Brozic, P.; Golob, B.; Gomboc, N.; Rizner, T.L.; Gobec, S.
Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3)
Mol. Cell. Endocrinol.
248
233-235
2006
Homo sapiens
brenda
Moeller, G.; Adamski, J.
Multifunctionality of human 17beta-hydroxysteroid dehydrogenases
Mol. Cell. Endocrinol.
248
47-55
2006
Homo sapiens
brenda
Parthasarathy, C.; Balasubramanian, K.
Effects of corticosterone deficiency and its replacement on Leydig cell steroidogenesis
J. Cell. Biochem.
104
1671-1683
2008
Rattus norvegicus (O54939)
brenda
Hu, G.X.; Zhou, H.Y.; Li, X.W.; Chen, B.B.; Xiao, Y.C.; Lian, Q.Q.; Liang, G.; Kim, H.H.; Zheng, Z.Q.; Hardy, D.O.; Ge, R.S.
The (+)- and (-)-gossypols potently inhibit both 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 in human and rat testes
J. Steroid Biochem. Mol. Biol.
115
14-19
2009
Homo sapiens, Rattus norvegicus
brenda
Day, J.M.; Tutill, H.J.; Foster, P.A.; Bailey, H.V.; Heaton, W.B.; Sharland, C.M.; Vicker, N.; Potter, B.V.; Purohit, A.; Reed, M.J.
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3
Mol. Cell. Endocrinol.
301
251-258
2009
Homo sapiens
brenda
Nakamura, Y.; Hornsby, P.; Casson, P.; Morimoto, R.; Satoh, F.; Xing, Y.; Kennedy, M.; Sasano, H.; Rainey, W.
Type 5 17-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis
J. Clin. Endocrinol. Metab.
94
2192-2198
2009
Homo sapiens
brenda
Jackson, V.J.; Yosaatmadja, Y.; Flanagan, J.U.; Squire, C.J.
Structure of AKR1C3 with 3-phenoxybenzoic acid bound
Acta Crystallogr. Sect. F
68
409-413
2012
Homo sapiens (P42330)
brenda
Adeniji, A.O.; Twenter, B.M.; Byrns, M.C.; Jin, Y.; Winkler, J.D.; Penning, T.M.
Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3)
Bioorg. Med. Chem. Lett.
21
1464-1468
2011
Homo sapiens (P42330)
brenda
Chen, M.; Adeniji, A.O.; Twenter, B.M.; Winkler, J.D.; Christianson, D.W.; Penning, T.M.
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer
Bioorg. Med. Chem. Lett.
22
3492-3497
2012
Homo sapiens (P42330)
brenda
Harada, K.; Kubo, H.; Tanaka, A.; Nishioka, K.
Identification of oxazolidinediones and thiazolidinediones as potent 17beta-hydroxysteroid dehydrogenase type 3 inhibitors
Bioorg. Med. Chem. Lett.
22
504-507
2012
Homo sapiens (P37058)
brenda
Sinreih, M.; Sosic, I.; Beranic, N.; Turk, S.; Adeniji, A.O.; Penning, T.M.; Rizner, T.L.; Gobec, S.
N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3
Bioorg. Med. Chem. Lett.
22
5948-5951
2012
Homo sapiens (P42330)
brenda
Maltais, R.; Fournier, M.A.; Poirier, D.
Development of 3-substituted-androsterone derivatives as potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 3
Bioorg. Med. Chem.
19
4652-4668
2011
Homo sapiens (P37058)
brenda
Harada, K.; Kubo, H.; Abe, J.; Haneta, M.; Conception, A.; Inoue, S.; Okada, S.; Nishioka, K.
Discovery of potent and orally bioavailable 17beta-hydroxysteroid dehydrogenase type 3 inhibitors
Bioorg. Med. Chem.
20
3242-3254
2012
Homo sapiens (P37058), Rattus norvegicus
brenda
Yuan, K.; Zhao, B.; Li, X.W.; Hu, G.X.; Su, Y.; Chu, Y.; Akingbemi, B.T.; Lian, Q.Q.; Ge, R.S.
Effects of phthalates on 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities in human and rat testes
Chem. Biol. Interact.
195
180-188
2012
Rattus norvegicus, Homo sapiens (P37058)
brenda
Matsunaga, T.; Hojo, A.; Yamane, Y.; Endo, S.; El-Kabbani, O.; Hara, A.
Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers
Chem. Biol. Interact.
202
234-242
2013
Homo sapiens (P42330)
brenda
Legeza, B.; Balazs, Z.; Nashev, L.G.; Odermatt, A.
The microsomal enzyme 17beta-hydroxysteroid dehydrogenase 3 faces the cytoplasm and uses NADPH generated by glucose-6-phosphate dehydrogenase
Endocrinology
154
205-213
2013
Homo sapiens (P37058)
brenda
Heinrich, D.M.; Flanagan, J.U.; Jamieson, S.M.; Silva, S.; Rigoreau, L.J.; Trivier, E.; Raynham, T.; Turnbull, A.P.; Denny, W.A.
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3
Eur. J. Med. Chem.
62
738-744
2013
Homo sapiens (P42330)
brenda
Gazvoda, M.; Beranic, N.; Turk, S.; Burja, B.; Kocevar, M.; Rizner, T.L.; Gobec, S.; Polanc, S.
2,3-diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17?-hydroxysteroid dehydrogenase (AKR1C3)
Eur. J. Med. Chem.
62
89-97
2013
Homo sapiens (P42330)
brenda
Zakharov, V.; Lin, H.K.; Azzarello, J.; McMeekin, S.; Moore, K.N.; Penning, T.M.; Fung, K.M.
Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma
Int. J. Clin. Exp. Pathol.
3
608-617
2010
Homo sapiens (P42330)
brenda
Miller, V.L.; Lin, H.K.; Murugan, P.; Fan, M.; Penning, T.M.; Brame, L.S.; Yang, Q.; Fung, K.M.
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma
Int. J. Clin. Exp. Pathol.
5
278-289
2012
Homo sapiens
brenda
Brozic, P.; Turk, S.; Adeniji, A.O.; Konc, J.; Janezic, D.; Penning, T.M.; Lanisnik Rizner, T.; Gobec, S.
Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library
J. Med. Chem.
55
7417-7424
2012
Homo sapiens (P42330)
brenda
Byrns, M.C.; Mindnich, R.; Duan, L.; Penning, T.M.
Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride
J. Steroid Biochem. Mol. Biol.
130
7-15
2012
Homo sapiens (P42330)
brenda
Latif, S.A.; Shen, M.; Ge, R.S.; Sottas, C.M.; Hardy, M.P.; Morris, D.J.
Role of 11beta-OH-C(19) and C(21) steroids in the coupling of 11beta-HSD1 and 17beta-HSD3 in regulation of testosterone biosynthesis in rat Leydig cells
Steroids
76
682-689
2011
Rattus norvegicus (O54939)
brenda
Amano, Y.; Yamaguchi, T.; Niimi, T.; Sakashita, H.
Structures of complexes of type 5 17beta-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding
Acta Crystallogr. Sect. D
71
918-927
2015
Homo sapiens (P42330)
brenda
Djigoue, G.B.; Kenmogne, L.C.; Roy, J.; Poirier, D.
Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3
Bioorg. Med. Chem. Lett.
23
6360-6362
2013
Rattus norvegicus
brenda
Djigoue, G.B.; Kenmogne, L.C.; Roy, J.; Maltais, R.; Poirier, D.
Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3
Bioorg. Med. Chem.
23
5433-5451
2015
Homo sapiens
brenda
Skarydova, L.; Hofman, J.; Chlebek, J.; Havrankova, J.; Kosanova, K.; Skarka, A.; Hostalkova, A.; Plucha, T.; Cahlikova, L.; Wsol, V.
Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors
J. Steroid Biochem. Mol. Biol.
143
250-258
2014
Homo sapiens (P42330)
brenda
Roy, J.; Fournier, M.A.; Maltais, R.; Kenmogne, L.C.; Poirier, D.
Reprint of in vitro and in vivo evaluation of a 3beta-androsterone derivative as inhibitor of 17beta-hydroxysteroid dehydrogenase type 3
J. Steroid Biochem. Mol. Biol.
153
170-178
2015
Rattus norvegicus (O54939), Homo sapiens (P37058), Rattus norvegicus Sprague-Dawley (O54939)
brenda
Cheng, Y.; Yang, Y.; Wu, Y.; Wang, W.; Xiao, L.; Zhang, Y.; Tang, J.; Huang, Y.D.; Zhang, S.; Xiang, Q.
The curcumin derivative, H10, suppresses hormone-dependent prostate cancer by inhibiting 17beta-hydroxysteroid dehydrogenase type 3
Front. Pharmacol.
11
637
2020
Homo sapiens (P37058)
brenda
Yazawa, T.; Imamichi, Y.; Uwada, J.; Sekiguchi, T.; Mikami, D.; Kitano, T.; Ida, T.; Sato, T.; Nemoto, T.; Nagata, S.; Islam Khan, M.R.; Takahashi, S.; Ushikubi, F.; Suzuki, N.; Umezawa, A.; Taniguchi, T.
Evaluation of 17beta-hydroxysteroid dehydrogenase activity using androgen receptor-mediated transactivation
J. Steroid Biochem. Mol. Biol.
196
105493
2020
Homo sapiens
brenda
Ning, X.; Yang, Y.; Deng, H.; Zhang, Q.; Huang, Y.; Su, Z.; Fu, Y.; Xiang, Q.; Zhang, S.
Development of 17beta-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy
Steroids
121
10-16
2017
Homo sapiens (P37058)
brenda